Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
Hong Kong
· Delayed Price · Currency is HKD 0.125
+0.001 (0.81%)
Apr 29, 2026, 3:58 PM HKT
HKG:8329 Revenue
In the year 2025, Shenzhen Neptunus Interlong Bio-technique Company had annual revenue of 972.01M CNY, down -6.69%. Shenzhen Neptunus Interlong Bio-technique Company had revenue of 476.09M in the half year ending December 31, 2025, a decrease of -6.53%.
Revenue
972.01M CNY
Revenue Growth
-6.69%
P/S Ratio
0.19
Revenue / Employee
703.34K CNY
Employees
1,382
Market Cap
208.07M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 972.01M | -69.69M | -6.69% |
| Dec 31, 2024 | 1.04B | -23.16M | -2.18% |
| Dec 31, 2023 | 1.06B | 78.17M | 7.92% |
| Dec 31, 2022 | 986.69M | 147.89M | 17.63% |
| Dec 31, 2021 | 838.81M | -192.56M | -18.67% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Extrawell Pharmaceutical Holdings | 52.65M |
| Tianda Pharmaceuticals | 322.95M |
| Regent Pacific Group | 2.83M |
| Joyzyme Group | 31.47M |
| PuraPharm Corporation | 336.11M |
| Kontafarma China Holdings | 914.71M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| China NT Pharma Group Company | 26.88M |